Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of NTQ1062 in Combination With Fulvestrant Versus Placebo Plus Fulvestrant in Patients With Locally Advanced (Unresectable) or Metastatic HR+/HER2- Breast Cancer Who Relapsed or Progressed During or After Endocrine Therapy.
NCT07393321 is registered in ClinicalTrials.gov with Nanjing Chia-tai Tianqing Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of NTQ1062 in Combination With Fulvestrant Versus Placebo Plus Fulvestrant in Patients With Locally Advanced (Unresectable) or Metastatic HR+/HER2- Breast Cancer Who Relapsed or Progressed During or After Endocrine Therapy.
- Lead sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- February 10, 2026
- Completion date
- August 31, 2031
- Enrollment
- 210 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
hr positive/her2 negative advanced or metastatic breast cancer